Trial reportThe American journal of clinical nutrition2025
Heme iron compared with ferrous iron salts to treat iron deficiency anemia in Gambian children: a randomized controlled trial.
Trial report in The American journal of clinical nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSupplementation with conventional ferrous salts has limited efficacy in controlling anemia and improving iron status in children at high risk of inflammation. We assessed whether heme iron polypeptide (HIP), an alternative form of supplemental iron with a distinct absorption pathway, might improve outcomes.
objectivesWe compared hemoglobin and ferritin concentrations in anemic Gambian infants aged 6-12 mo after supervised daily oral supplementation with HIP or ferrous sulfate.
methodsBetween March 2023 and February 2024, 208 anemic infants, aged 6-12 mo (hemoglobin, 7.0 to <11.0 g/dL) were randomly assigned to 84 d of directly observed daily supplementation with 10 mg elemental iron as HIP or ferrous sulfate. Primary outcomes were hemoglobin and ferritin concentrations at end of intervention. Analysis was by intention-to-treat with multiple imputations to replace missing data.
resultsAdherence to treatments was ∼90%. The primary end points of hemoglobin and ferritin concentrations both improved by day 84 with no difference between treatments. For the secondary end point of anemia, the prevalence went from 83.7% to 46.2% in the ferrous sulfate group and from 84.6% to 47.1% in the HIP group. Infants who received HIP had higher serum iron concentration (by 48.4%; 95% CI: 15.4%, 91.0%), higher transferrin saturation (by 52.3%; 95% CI: 17.9%, 96.7%), lower soluble transferrin receptor concentrations (by -9.7%; 95% CI: -16.3%, -2.6%) and lower unsaturated iron-binding capacity (by -7.8%; 95% CI: -13.4%, -1.7%). In a post hoc analysis, HIP had a greater effect on inflammation-adjusted serum ferritin concentrations (by 22.9%; 95% CI: 5.6%, 43.1%). No group differences were found in the frequency of adverse events.
conclusionsThere is no benefit of HIP on the primary end points of hemoglobin and ferritin. However, HIP is superior to ferrous sulfate for 5 secondary measures of iron status and might therefore improve iron supply to rapidly developing organs. This trial is registered with the Pan African Clinical Trial Registry as PACTR202210523178727 (https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=23910).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.